Stem Cell Breast Augmentation vs SVF Breast Augmentation
كل الحقائق أدناه مأخوذة من صفحتَي العنصرين ومصادرهما. تُقارَن أولًا البنود المسجّلة لدى الجانبين، ثم تُعرض البقية جنبًا إلى جنب.
مفهوم
Stem Cell Breast AugmentationA consumer and marketing term for breast fat grafting enriched with stromal vascular fraction or adipose-derived cells. It is not a separate regulated procedure category.تاريخ التحديث 21 سبتمبر 2026طبي
SVF Breast AugmentationSVF breast augmentation is breast fat grafting in which the injected fat is enriched with the patient's own stromal vascular fraction.تاريخ التحديث 21 سبتمبر 2026العلاقة بينهماStem Cell Breast Augmentation — يشير عادةً إلى → SVF Breast Augmentation
بنود مشتركة
0 بند مسجّل على الجانبينلا يوجد بعد بند مسجّل لدى الاثنين معًا. الحقائق الموثّقة لكل جانب موضّحة أدناه.
حقائق كل جانب
حقائق موثّقة مسجّلة لدى أحد الجانبين فقط.
Stem Cell Breast Augmentation
لا توجد قيمة موثّقة بعد
SVF Breast Augmentation
DefinitionAutologous fat grafting in which SVF isolated from part of the aspirated fat is recombined with the remaining fat before injection, turning progenitor-poor aspirated fat into progenitor-rich fat
First described for cosmetic breast augmentationYoshimura K et al., Aesthetic Plastic Surgery 32(1):48–55 (2008); 40 patients, mean ~270 mL fat injected per breast, final gain 100–200 mL
Complications in original seriesCysts (<12 mm) on MRI in 2 patients; microcalcification on mammogram in 2 patients at 24 months; 1 case of sternal fibrosis
Breast augmentation meta-analysis (Li & Chen)6 studies, 353 patients: CAL had higher fat survival (SMD 1.79, 95% CI 0.28–3.31); complications did not differ significantly (OR 1.34); the SVF-enriched subgroup showed no survival difference
Meta-analysis across recipient sites (Sutar et al.)15 studies: graft survival favored enriched grafts (SMD 2.44), with very high heterogeneity (I² = 97.19%); benefit was context-dependent
US FDA positionAdipose-derived SVF fails the minimal-manipulation criterion (21 CFR 1271.10(a)(1)) and needs an IND or an approved BLA as a drug/biologic
US court ruling on same-day SVFNinth Circuit (Sept 2024) held SVF procedures do not qualify for the same-surgical-procedure exemption; the Supreme Court declined review on 2025-10-15
Korea: Advanced Regenerative Bio Act amendmentEffective 2025-02-21: regenerative-medicine treatment allowed only for serious, rare or intractable diseases, at designated institutions, with review-committee approval of treatment plans
Reported safety concernsCyst formation 6.9% with automated vs 1.6% with manual isolation in cited data; theoretical oncogenic concern from VEGF/FGF signalling; long-term oncologic data insufficient
Method standardizationNo standardized CAL protocol; multiple isolation systems in use (e.g., Celution, Medikhan, Fatstem, Mystem)
Reported outcome (SC301-authored, 2023)Average injected volume 162.35 mL (left breast); retention 78.65% (3 mo), 77.17% (6 mo), 77.48% (18 mo, n=102)
Reported outcome (SC301-authored, 2020)In 105 patients, engraftment 85.1% (1 mo), 75.1% (3 mo), 73.7% (6 mo); patients receiving >60 million ADSC had 90.5% vs 68.9% for <60 million
Evidence levelSingle-center, provider-authored series; no independent randomized controlled data identified as of 2026-09